Cardiovascular disease is responsible for more than 600,000 deaths each year in the US, and more than half of these are due to coronary heart disease (CHD). Myocardial perfusion imaging (MPI) is one of the most effective tools for assessing CHD, and according to the most recent estimate, this technique accounts for >50% of all nuclear medicine studies in adults, nearly 6 million scans in 2014. At present, most of these studies are carried out using 99mTc-MIBI and 99mTc-tetrofosmin, despite the significant limitations of SPECT (single photon emission computed tomography) for MPI including lower spatial resolution than PET (positron-emission tomography); the lack of routine attenuation corrections, which are of particular importance in an increasingly obese population; and the challenge of measuring myocardial blood flow (MBF), which is critical to accurately evaluating global ischemia and microvessel disease. This investigation, ?A Novel F-18 PET Myocardial Perfusion Radiopharmaceutical based on Rhodamine Dyes,? builds upon a currently funded project of the same title, 1 R01 HL108107-01, that concludes on 1/31/2017. As in the foundational R01, the primary objective of this project is to develop an 18F-labeled radiopharmaceutical for PET imaging of myocardial perfusion.
The Specific Aims of the original project have been largely fulfilled; and thus, while our central hypothesis remains the same, i.e., that a PET myocardial perfusion imaging agent can be developed based on an 18F-labeled rhodamine dye, we have gathered sufficient preliminary results to initiate a first-in- human-study in the next project period. We have demonstrated that 18F-labeled rhodamine dyes accumulate impressively in the heart, which confirms their significant potential as PET MPI radiopharmaceuticals. The central hypothesis of this proposal is, therefore, unchanged: A PET radiopharmaceutical for the evaluation of myocardial perfusion can be developed based on an 18F-labeled rhodamine dye. We have tested and validated this basic premise in our laboratory and found that the 18F-labeled diethyleneglycol ester derivative of rhodamine 6G ([18 F]Rho6G) shows very high accumulation in the heart, minimal accumulation in the liver, and rapid blood clearance. While 18 F-Rho6G has shown great promise as an MPI agent, we do not yet know if it will perform optimally in humans. Thus, we will explore additional rhodamine-like compounds as potential PET radiotracers for MPI. Accordingly, the new Specific Aims will first build upon our findings with 18F- Rho6G by a) carrying out a first-in-human study with [18F]Rho6G; b) measuring the extraction fraction of 18F- Rho6G, a critical parameter for a clinically useful MPI radiopharmaceutical; and c) evaluating a number of novel rhodamine derivatives and also assessing alternatives cores in anticipation of the possible need for an alternative to rhodamine dyes for human use. Our successful accomplishment of these Specific Aims will lead to the development of a novel and effective PET radiopharmaceutical for MPI that will significantly improve clinical management of patients with CHD by providing an accurate measure of myocardial perfusion.

Public Health Relevance

Cardiovascular disease is responsible for more than 600,000 deaths each year in the US, and more than half of these deaths are due to coronary heart disease (CHD). Myocardial perfusion imaging (MPI) is one of the most effective tools for assessing CHD, and according to the most recent estimate, this technique accounts for more than 50% of all nuclear medicine studies in adults?nearly 6 million scans in 2014. However, there are significant limitations to MPI as it is currently used because SPECT (single photon emission computed tomography) lacks sufficient sensitivity and specificity for optimal disease management. Our preliminary studies have shown that 18F-labeled rhodamine dyes accumulate impressively in the heart, which suggests their significant potential as improved MPI radiopharmaceuticals. The primary goal of this new investigation, therefore, is twofold: first, to build on the successful fulfilment of Specific Aims in our original project; and second, to continue to develop an 18F-labeled radiopharmaceutical for PET imaging of myocardial perfusion that can accurately assess cardiac disease and enable improved disease management of CHD in both the short- and long-term.

Agency
National Institute of Health (NIH)
Institute
National Heart, Lung, and Blood Institute (NHLBI)
Type
Research Project (R01)
Project #
5R01HL108107-07
Application #
9774279
Study Section
Clinical Molecular Imaging and Probe Development (CMIP)
Program Officer
Sopko, George
Project Start
2011-04-01
Project End
2021-06-30
Budget Start
2019-07-01
Budget End
2020-06-30
Support Year
7
Fiscal Year
2019
Total Cost
Indirect Cost
Name
Boston Children's Hospital
Department
Type
DUNS #
076593722
City
Boston
State
MA
Country
United States
Zip Code
02115
Inkster, J A H; Zhang, S; Akurathi, V et al. (2017) New chemical and radiochemical routes to [18F]Rho6G-DEG-F, a delocalized lipophilic cation for myocardial perfusion imaging with PET. Medchemcomm 8:1891-1896
Cowan, Douglas B; Yao, Rouan; Akurathi, Vamsidhar et al. (2016) Intracoronary Delivery of Mitochondria to the Ischemic Heart for Cardioprotection. PLoS One 11:e0160889
Bartholomä, Mark D; Zhang, Shaohui; Akurathi, Vamsidhar et al. (2015) (18)F-labeled rhodamines as potential myocardial perfusion agents: comparison of pharmacokinetic properties of several rhodamines. Nucl Med Biol 42:796-803
Bartholoma, Mark D; He, Huamei; Pacak, Christina A et al. (2013) Biological characterization of F-18-labeled rhodamine B, a potential positron emission tomography perfusion tracer. Nucl Med Biol 40:1043-8
Bartholomä, Mark D; Gottumukkala, Vijay; Zhang, Shaohui et al. (2012) Effect of the prosthetic group on the pharmacologic properties of 18F-labeled rhodamine B, a potential myocardial perfusion agent for positron emission tomography (PET). J Med Chem 55:11004-12